ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,222.68
      0.16%
      US Tech 100
      17,650.00
      0.05%
      Dow Jones
      39,512.84
      0.32%
      Brent Oil
      82.585
      0.00%
      Bitcoin
      60,921.43
      0.21%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Silence Therapeutics PLC (SLN)

      7. Silence Therapeutics PLC (SLN) News

      SLN

      Silence Therapeutics (SLN)

      Silence Therapeutics PLC
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SLN
      DateTimeSourceHeadlineSymbolCompany
      05/08/20245:14PMEdgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:SLNSilence Therapeutics PLC
      04/30/20248:30AMBusiness WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
      04/29/20248:30AMBusiness WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsNASDAQ:SLNSilence Therapeutics PLC
      04/08/202411:48AMBusiness WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
      03/13/20247:05AMBusiness WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
      03/13/20247:03AMIH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
      03/13/20247:00AMBusiness WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
      02/28/20248:00AMBusiness WireSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024NASDAQ:SLNSilence Therapeutics PLC
      02/23/20248:12AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
      02/23/20248:00AMBusiness WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialNASDAQ:SLNSilence Therapeutics PLC
      02/14/20249:54AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
      02/14/20248:55AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
      02/05/20248:00AMBusiness WireSilence Therapeutics Announces Oversubscribed $120 Million Private PlacementNASDAQ:SLNSilence Therapeutics PLC
      01/31/20247:00AMBusiness WireSilence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:SLNSilence Therapeutics PLC
      12/01/20237:00AMBusiness WireSilence Therapeutics Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:SLNSilence Therapeutics PLC
      11/14/20237:00AMBusiness WireSilence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:SLNSilence Therapeutics PLC
      11/08/20237:00AMBusiness WireSilence Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
      11/01/20237:00AMBusiness WireSilence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular DiseaseNASDAQ:SLNSilence Therapeutics PLC
      09/26/20237:00AMBusiness WireSilence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines ConferenceNASDAQ:SLNSilence Therapeutics PLC
      09/06/20237:00AMBusiness WireSilence Therapeutics to Participate in September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
      08/29/20234:01PMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:SLNSilence Therapeutics PLC
      08/16/20237:00AMBusiness WireSilence Therapeutics Reports Second Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
      08/01/20234:31PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNSilence Therapeutics PLC
      07/11/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
      07/11/20237:00AMBusiness WireSilence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
      05/31/20237:00AMBusiness WireSilence Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
      05/16/20234:02PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:SLNSilence Therapeutics PLC
      05/16/20234:00PMBusiness WireSilence Therapeutics Reports First Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
      05/04/20237:00AMBusiness WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca CollaborationNASDAQ:SLNSilence Therapeutics PLC
      05/01/20237:32AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:SLNSilence Therapeutics PLC
       Showing the most relevant articles for your search:NASDAQ:SLN